Login / Signup

Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes.

Kazuyuki NumakuraMizuki KobayashiShingo HatakeyamaSei NaitoYohei HorikawaToshikazu TanakaSachiko KamadaYumina MutoRyohei YamamotoAtsushi KoizumiTaketoshi NaraSohei KandaMitsuru SaitoShintaro NaritaTakamitsu InoueNaotake ShimodaNorihiko TsuchiyaChikara OhyamaTomonori Habuchi
Published in: International journal of clinical oncology (2020)
Nivolumab's effectiveness was comparable between the two patient groups, except for early AE-related discontinuation in the ≥ 75 year group.
Keyphrases
  • renal cell carcinoma
  • end stage renal disease
  • newly diagnosed
  • randomized controlled trial
  • prognostic factors
  • peritoneal dialysis
  • case report
  • patient reported
  • drug induced